Point of Care Rheological Assay for Sickle Cell Disease

Published date: March 7, 2016

Technology description

Summary

Vanderbilt researchers have created a novel technology for the diagnosis and monitoring of disease states using the rheological properties of a blood sample with a lateral flow membrane.

Addressed Need

Sickle Cell Disease (SCD) is expected to afflict over 14 million newborns by 2050 and there is an acute need for early diagnosis of the disease in low resource setting. Current diagnostics require highly trained personnel, are limited to laboratory settings , and fail to provide a viable alternative to the gold-standard HPLC analysis. There is a market opportunity for new technologies that provide clinically relevant assessments of sickling hemoglobin levels, such as the concentration of hemoglobin S, in a sample to aid in the diagnosis and management of SCD.



Advantages

Low-cost lateral flow diagnostic
Quick evaluation of results without the need for specialized equipment
Results easy to understand
Rapid diagnosis and quantification of Hemoglobin S

Institution

Vanderbilt University

联系我们

叶先生

电 话：021-65679356
手 机：13414935137
邮 箱：yeyingsheng@zf-ym.com